CR Bard has reported net sales of $673.9m for the second quarter 2010, an increase of 8% over the prior-year period.
CR Bard has posted net sales of $464.9m in the US and $209m outside the US, an increase of 7% and 9%, respectively, compared with the second quarter of 2009.
CR Bard has posted net income of $124.6m and $1.29 diluted earnings per share available to common shareholders, an increase of 11% and 16%, respectively, as compared to second quarter 2009.
For the six months ended June 30, 2010, the company has posted net sales $1,325m compared to net sales of $1,221m for the same period of 2009.
Timothy Ring, chairman and chief executive officer, said: “Bard delivered strong EPS growth this quarter, fueled by a record gross margin performance, while accelerating organic investment in R&D.
“We are dedicated to driving revenue growth by offering our customers products that are clinically and economically differentiated. Looking ahead, we see ample opportunity to expand our investment in the development and acquisition of market-leading technologies.”